Targets › GNRH1R
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jul 2028.
Open in Phaseline: the race on GNRH1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | Gonadotropin-releasing Hormone Analog GnRH receptor agonist; suppresses LH and FSH to reduce testosterone production | GNRH1R | Phase 2 | Oligometastatic Prostate Carcinoma | Jul 2028 |
Oligometastatic Prostate Carcinoma (1)
mixed (1)
Mayo Clinic (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.